PROTHENA CORP PLC (PRTA)       54.96  -2.16 (-3.78%)

54.96  -2.16 (-3.78%)

IE00B91XRN20 - Common Stock - After market: 54.96 0 (0%)

PROTHENA CORP PLC54.96

NASDAQ:PRTA (1/30/2023, 7:16:30 PM)-2.16 (-3.78%)

After market: 54.96 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-13 2023-02-13
Ins Owners 0.04% Inst Owners 86.27%
Market Cap 2.84B Shares 51.63M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86.67
IPO 12-21 2012-12-21

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PRTA Daily chart

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The firm is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The firm's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.

Company Info

PROTHENA CORP PLC

77 Sir John Rogersons Quay, Block C, Grand Canal Docklands

DUBLIN D02 VK60

P: 35312362500.0

CEO: Gene G. Kinney

Employees: 82

Website: http://www.prothena.com/

PRTA News

News Image2 months ago - Seeking AlphaProthena prices 3.25M shares public offering (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA) priced an underwritten public offering of 3.25M shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering...

News Image2 months ago - Prothena Corporation plcProthena Announces Pricing of Public Offering of 3,250,000 Ordinary SharesNews Image2 months ago - Market News VideoNotable Wednesday Option Activity: TRUP, STNG, PRTANews Image2 months ago - Prothena Corporation plcProthena Announces Proposed Public Offering of Ordinary SharesNews Image2 months ago - Prothena Corporation plcProthena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022News Image2 months ago - Prothena Corporation plcProthena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

PRTA Twits

Here you can normally see the latest stock twits on PRTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example